Guardian ubiquitin E3 ligases target cancer-associated APOBEC3 deaminases for degradation to promote human genome integrity

Read full text
Authors: Irene Schwartz, Valentina Budroni, Mathilde Meyenberg, Zuzana Hodáková, Harald Hornegger, Kathrin Hacker, Siegfried Schwartz, Daniel B. Grabarczyk, Julian F. Ehrmann, Sara Scinicariello, David Haselbach, Jörg Menche
+3 more Tim Clausen, G. Elif Karagöz, Gijs A. Versteeg
Cited by: 3
References: 126

Abstract

APOBEC family members play crucial roles in antiviral restriction. However, certain APOBEC3 (A3) proteins drive harmful hypermutation in humans, contributing to cancer. The cancer-associated A3 proteins are capable of transiting from the cytosol to the nucleus, where they can cause genome mutations. Here, we uncover a specific set of cellular pathways that protect genomic DNA from the major cancer-associated A3 proteins. Through genetic and proteomic screening, we identify UBR4, UBR5, and HUWE1 as key ubiquitin E3 ligases marking cancer-associated A3B and A3H-I for degradation, thereby limiting A3-driven hypermutation. Mechanistically, UBR5 and HUWE1 recognize A3s in the absence of their RNA binding partner, thus promoting proteasomal degradation of APOBEC3 protein that is not engaged in its antiviral cellular function. Depletion or mutation of the E3 ligases in cells and human cancer samples increases A3-driven genome mutagenesis. Our findings reveal that UBR4, UBR5, and HUWE1 are crucial factors in a ubiquitination cascade that maintains human genome stability.

Fields of Study & Subjects

Ubiquitin and proteasome pathways interferon and immune responses HIV/AIDS drug development and treatment

Publication details

Journal / source
Nature Communications
Publisher
Springer Science and Business Media LLC
Volume
17
Issue
1
Pages
1723–1723
Publication date
19 January 2026
Language
EN